

**NHS AYRSHIRE & ARRAN  
PATIENT GROUP DIRECTION**

<b>Name of Medicine :</b>	Patient Group Direction for the immediate provision of medicines and appliances listed in the BNF and BNFC, to NHS patients by pharmacists in response to e-mail request from an Ayrshire Urgent Care Service (AUCS) prescriber, email request from NHS Ayrshire and Arran Trauma and Orthopaedics or Combined Assessment Unit/Emergency Department (CAU/ED) teams		
<b>Legal Classification :</b>	POM		
<b>PGD Ref No :</b>	CP 24 066		
<b>Replacing PGD Ref No :</b>	N/A		
<b>Effective Date :</b>	4 <sup>th</sup> March 2024		
<b>Review Date :</b>	3 <sup>rd</sup> March 2026		
<b>Professional Group authorised to use PGD on completion and submission of an Approved Practitioner Form:</b>	Pharmacist whose name is currently on the practising section of the pharmaceutical register held by the General Pharmaceutical Council (GPhC).		
<b>Specialist competencies or qualifications:</b>	Has undertaken appropriate training for working under PGDs for the supply and administration of medicines		
<b>Continuing education &amp; training:</b>	The practitioner should be aware of any change to the recommendations for the medicine listed. It is the responsibility of the individual to keep up-to-date with continued professional development		
<b>PGD prepared/reviewed* by :</b>			
	<b>Doctor</b>	<b>Pharmacist</b>	<b>Other</b>
<b>Name</b>	Dr Scott McCulloch	Iain Fulton	Joanna Woodburn Clinical Nurse Manager- Ayrshire Urgent Care Services. Mahanth Manuel – Associate Medical Director UHA Nancy Wallace Clinical Nurse Manager - Acute CAU / Emergency Care
<b>Signature</b>			
<b>Date</b>	01/03/2024	01/03/2024	01/03/2024 01/03/2024 01/03/2024
<b>Approved on behalf of NHS Ayrshire &amp; Arran</b>			
<b>Chair or vice chair PGD group:</b>			
<b>Name:</b> Jen Pennycook			
<b>Signature:</b>			<b>Date:</b> 04/03/2024

<b>Description of Treatment</b>	
<p>Name of medicine :</p> <p>All medicines and/or appliances as listed in BNF and BNFC described in part A in the schedules of this PGD.</p> <p>As detailed by the patient's consulting AUCS clinician via e-mail received in community pharmacy clinical mailbox from ADASTRA system.</p> <p>Or</p> <p>As detailed by the NHS A&amp;A Trauma and Orthopaedic or Combined Assessment Unit/Emergency Department (CAU/ED) Hospital discharge letter via e-mail received in community pharmacy clinical mailbox from HEPMA system</p> <p>Variation of product brand and/or dosage form and/or strength may be substituted when listed product cannot be supplied within a reasonable time provided the active drug base and dose and dosage regimen is equivalent.</p>	
POM/P/GSL :	POM
Pharmaceutical Form :	As described in the BNF or BNFC
Strength :	
Supply, Administer or Both:	Supply only.
Additional Monitoring:	No
Is the use out with the Summary of Product Characteristics (SPC)	No
Storage requirements:	Store in a secure location.
Clinical situation for use of this PGD	The provision from a pharmacy with an NHS contract of NHS prescribed medicines and/or appliances required when the patient has had a consultation with AUCS or hospital discharge from NHS A&A Trauma and Orthopaedics or Combined Assessment Unit/Emergency Department and requires an immediate supply of medication as described in part A in the schedules of this PGD

Inclusion criteria	<ul style="list-style-type: none"> <li>• New or Changed Medicines and/or appliances required for immediate supply following AUCS consultation or NHS A&amp;A Trauma and Orthopaedic or Combined Assessment Unit/Emergency Department hospital discharge and e-mail received in the community pharmacy from the ADASTRA or HEPMA system.</li> <li>• Medicines and/or appliances are allowed on NHS prescription and are not listed in part B in the schedules of this PGD</li> <li>• Patient is registered (or temporarily) with a medical practice in Scotland</li> <li>• Patient agrees to relevant clinical information being provided to the pharmacist by the consulting clinician.</li> <li>• Patient agrees that all relevant clinical information is shared between their GP, Community Pharmacy, Ayrshire urgent care services team, NHS A&amp;A Trauma and Orthopaedic or Combined Assessment Unit/Emergency Department teams.</li> </ul> <p><b>Patient consulted by AUCS clinician or NHS A&amp;A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team and access to emailed ADASTRA or HEPMA message allows confirmation of inclusion criteria point 1 above</b></p>
--------------------	--

Exclusion criteria	<ul style="list-style-type: none"> <li>• Provision is not required immediately following an urgent care consultation or hospital discharge from NHS A&amp;A Trauma and Orthopaedics or Combined Assessment Unit/Emergency Department.</li> <li>• Medicines and/or appliances which are listed in part B in the schedules of this PGD or are not allowed on NHS prescription</li> <li>• No agreement to share relevant clinical information</li> <li>• Where the pharmacist is unable to satisfactorily resolve any discrepancies with the clinician involved.</li> </ul>
Dosage :	As detailed in the e-mailed ADASTRA or HEPMA message or following clarification with the patient and/or AUCS, NHS A&A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team (if required)
Total Dosage:	As detailed in the e-mailed ADASTRA or HEPMA message or following clarification with the patient and/or AUCS or NHS A&A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team (if required)

Route of Administration :	As detailed in the e-mailed ADASTRA or HEPMA message or following clarification with the patient and/or AUCS or NHS A&A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team (if required)
Frequency of Administration :	As detailed in the e-mailed ADASTRA or HEPMA message or following clarification with the patient and/or AUCS or NHS A&A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team (if required)
Duration of Treatment :	As detailed in the e-mailed ADASTRA or HEPMA message or following clarification with the patient and/or AUCS or NHS A&A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team (if required)
Total Treatment Quantity :	As detailed in the e-mailed ADASTRA or HEPMA message or following clarification with the patient and/or AUCS or NHS A&A Trauma and Orthopaedic team or Combined Assessment Unit/Emergency Department team (if required)
Action if patient is excluded from treatment under this PGD or patient declines	Refer back to AUCS, NHS A&A Trauma and Orthopaedic or Combined Assessment Unit/Emergency Department teams.
Interactions	
Warnings including possible adverse reactions and management of these	<p>Please refer to current BNF or SPC for full details</p> <p>Adverse Effects As per BNF or BNFC</p> <p>Use the Yellow Card System to report adverse drug reactions. Yellow Cards and guidance on its use are available at the back of the BNF or online at <a href="http://yellowcard.mhra.gov.uk/">http://yellowcard.mhra.gov.uk/</a></p>
Follow-up treatment	
Written/Verbal Advice to be given to patient/carer	<p>Contact community pharmacy, GP or OOH if concerns with any medicine supplied.</p> <p>Provision of the appropriate Pharmaceutical Industry Patient Information Leaflet.</p> <p>Provision of any other relevant information as judged by the Pharmacist operating under this PGD.</p>
Referral arrangements for further advice/cautions:	Refer AUCS, NHS A&A Trauma and Orthopaedic team, NHS A&A Combined Assessment Unit/Emergency Department team or GP
Cautions/Need for further advice/Circumstances when further advice should be sought from the prescriber:	Where a patient attends the community pharmacy without a prior notification from AUCS, NHS A&A Trauma and Orthopaedics or NHS A&A combined assessment unit/Emergency Department, the community pharmacy will contact the AUCS, NHS A&A Trauma and Orthopaedic or NHS A&A combined assessment unit/Emergency Department team to resolve.
Monitoring (if applicable):	
Follow up:	None

Record required of Supply/Administration:	Dispensing episode recorded on community pharmacy PMR system. UCF prescription completed and sent electronically.
---	--

## Referral Arrangements and Audit Trail

<b>Referral arrangements</b>	<i>As per local arrangements/national guidelines</i>
<b>Records/audit trail:</b>	<p>E-mail received from AUCS via ADASTRA, or from NHS A&amp;A Trauma and Orthopaedics / Combined Assessment Unit/Emergency Department via HEPMA stored in an electronic folder within the community pharmacy clinical mailbox.</p> <p>Dispensing episode recorded on community pharmacy PMR system.</p> <p>UCF prescription completed and submitted electronically.</p>

<b>References/Resources and comments:</b>	<p>Notes:</p> <p>SPC – Summary of Product Characteristics</p> <p>BNF – British National Formulary</p>
---	---

## SCHEDULE 1

**PATIENT GROUP DIRECTION FOR THE IMMEDIATE PROVISION OF MEDICINES, APPLIANCES AND ACBS PRODUCTS LISTED IN THE BNF AND BNFC, TO NHS PATIENTS BY PHARMACISTS FOLLOWING A HOSPITAL ADMISSION.**

### **BNF/BNFC Class of Medicine: Gastro-intestinal system**

**Part A:** All medicines in Gastro-intestinal system, of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.:

**Part B:** The following medicines listed in Gastro-intestinal system, chapter 1 of the current BNF/BNFC may not be provided under this PGD.

<b>Excluded drug</b>	<b>Rationale</b>
All injections and infusions	Acute/Specialist use only
All section 2.1	Acute use only
All section 4.4	Diagnostic use only
Chenodeoxycholic Acid	Specialist use only
Cholic Acid	Specialist use only
Lubiprostone	Acute use only
Obeticholic acid	Specialist use only
Racecadotril	Acute use only

## SCHEDULE 2

BNF/BNFC Class of Medicine: Cardiovascular system, chapter 2

**Part A:** All medicines in Cardiovascular system, chapter 2 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Cardiovascular system, chapter 2 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections, infusions and intravenous flushes <b>except:</b> <u>Alirocumab</u> Emerade®, EpiPen® and Jext® injections for self-administration Dalteparin sodium injection Enoxaparin sodium injection Tinzaparin sodium injection	Acute/Specialist use only
All section 2.1	Specialist use only
All section 2.2	Specialist use only
All section 4.1a	Specialist use only
All section 4.1c	Specialist use only
All section 4.2 <b>except:</b> midodrine hydrochloride	Specialist use only
Lomitapide	Specialist use only
Mexiletine	Specialist use only
Metirosine	Specialist use only

### SCHEDULE 3

#### BNF/BNFC Class of Medicine: Respiratory system, chapter 3

**Part A:** All medicines in Respiratory system, chapter 3 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Respiratory system, chapter 3 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 5	Specialist use only
Grass pollen extract	Specialist Use only
Oxygen <sup>1</sup>	Alternative supply route

---

<sup>1</sup> Oxygen supplies should be obtained via Dolby Vivisol on 0800 833 531

## SCHEDULE 4

### BNF/BNFC Class of Medicine: Nervous system, chapter 4

**Part A:** All medicines in Nervous system, chapter 4 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Nervous system, chapter 4 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 3.2 <b>except:</b> Atomoxetine, Guanfacine	Controlled drug
All section 8.3	Controlled drug/Specialist use
Alfentanil	Controlled drug/Hospital Use
Aprepitant	Specialist use only
Buprenorphine	Controlled drug
Cannabidiol	Specialist use only
Capsaicin patches	Specialist use only
Clobazam <sup>2</sup>	Epilepsy only
Clozapine <sup>3</sup>	Registration required
Codeine phosphate oral solution	Potential for abuse
Diamorphine hydrochloride	Controlled drug
Dipipanone hydrochloride with cyclizine	Controlled drug
Fentanyl	Controlled drug

Tramadol	Controlled drug
Tryptophan	Specialist use only
Gabapentin	Controlled drug

<sup>2</sup> Clobazam can be supplied under the PGD for **epilepsy only and must be endorsed SLS**.

<sup>3</sup> Clozapine can be supplied under the PGD if the Pharmacy is registered for the patient monitoring service for that patient.

Hydromorphone hydrochloride	Controlled drug
Loxapine	Specialist use only
Melatonin <sup>4</sup>	Acute use only
Meprobamate	Controlled drug
Methoxyflurane	Close medical supervision only
Midazolam	Controlled drug
Morphine <sup>6</sup>	Controlled drug
Morphine with cyclizine	Controlled drug
Nabilone	Controlled drug/Hospital Use
Oxycodone Hydrochloride	Controlled drug
Oxycodone with naloxone	Controlled drug
Palonosetron	Specialist use only
Palonosetron with netupitant	Specialist use only
Paracetamol with tramadol	Controlled drug
Pentazocine	Controlled drug
Pethidine hydrochloride	Controlled drug
Pregabalin	Controlled drug
Rolapitant	Specialist use only
Sodium Oxybate	Specialist use only
Sufentanil	Controlled drug/Hospital Use
Tapentadol	Controlled drug
Temazepam	Controlled drug

<sup>4</sup> Only Circadin® can be supplied, provided the patient is currently receiving this brand.

<sup>6</sup> All strengths are not allowed on the PGD including oramorph 10mg/5ml.

## SCHEDULE 5

### BNF/BNFC Class of Medicine: Infections, chapter 5

**Part A:** All medicines in Infections, chapter 5 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Infections, chapter 5 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 1	Acute use only
All section 5 <b>except</b> Quinine for nocturnal leg cramps	Acute use only
All section 6.1	Specialist use only
All section 6.2	Specialist use only
All section 6.3	Specialist use only
All section 6.5	Specialist use only
All section 6.7	Specialist use only

---

## SCHEDULE 6

### BNF/BNFC Class of Medicine: Endocrine system, chapter 6

**Part A:** All medicines in Endocrine, chapter 6 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Endocrine system, chapter 6 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions <b>except</b> in section 3	Acute/Specialist use only/Controlled drug
Section 2.1	Specialist use only
All section 7	Specialist use only
All section 8.2 except section 8.2a	Controlled drug
Anhydrous glucose	Acute use only
Clomifene citrate	Specialist use only
Iodide with iodine	Acute use only

## SCHEDULE 7

### BNF/BNFC Class of Medicine: Genito-urinary system, chapter 7

**Part A:** All medicines in Genito-urinary system, chapter 7 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Genito-urinary system, chapter 7 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions <b>except</b> in section 3.5	Acute/Specialist use only
All intra-uterine devices	Time period between repeats
All section 2	Specialist use only
All section 3.2	Time period between repeats
All section 5	Specialist use only
Adcirca <sup>®</sup>	Specialist use only
Etonogestrel implant	Time period between repeats
Revatio <sup>®</sup>	Specialist use only

## SCHEDULE 8

### BNF/BNFC Class of Medicine: Malignant disease, chapter 8

**Part A:** All medicines in Malignant disease, chapter 8 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD:

**Part B:** The following medicines listed in Malignant disease, chapter 8 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions <b>except:</b> Metoject PEN <sup>®</sup> , Nordimet <sup>®</sup> and Zlatal <sup>®</sup> injections for self-administration	Acute/Specialist use only
All sections <b>except:</b> Malignant disease section 4 Hormone responsive malignancy Malignant disease section 4.1 Hormone responsive breast cancer Mercaptopurine Methotrexate	Specialist use only
Abiraterone acetate <sup>9</sup> Enzalutamide <sup>10</sup>	Monitoring required

<sup>8</sup> Patients receiving oral therapy with ciclosporin or tacrolimus should be maintained on their usual brand. Any change must be under the supervision of a specialist.

<sup>9</sup> Abiraterone acetate can be supplied under the PGD if the patient is within the required monitoring period. <sup>10</sup> Enzalutamide can be supplied under the PGD if the patient is within the required monitoring period.

## SCHEDULE 9

### BNF/BNFC Class of Medicine: Blood and nutrition, chapter 9

**Part A:** All medicines in Blood and nutrition, chapter 9 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.

**Part B:** The following medicines listed in Blood and nutrition, chapter 9 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions <b>except:</b> Blood and blood-forming organs section 1.1 and section 1.3	Acute/Specialist use only
All Blood and blood-forming organs section 2	Specialist use only
All Blood and blood-forming organs section 3	Specialist use only
All Nutrition and metabolic disorders section 1.5a Hyperkalaemia	Specialist use only
All Nutrition and metabolic disorders section 2 Metabolic disorders <b>except:</b> All drugs in section 2.2 All drugs in section 2.13	Specialist use only
Romiplostim	Specialist use only
Eltrombopag	Specialist use only
Oxymetholone	Controlled Drug

## SCHEDULE 10

### BNF/BNFC Class of Medicine: Musculoskeletal system, chapter 10

**Part A:** All medicines in Musculoskeletal, chapter 10 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.:

**Part B:** The following medicines listed in Musculoskeletal, chapter 10 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 3.1	Specialist use only
Baricitinib	Specialist use only
Leflunomide <sup>6</sup>	Monitoring required
Tofacitinib	Specialist use only

---

<sup>6</sup> Leflunomide can be supplied under the PGD if the patient is within the required monitoring period.

## SCHEDULE 11

24

### BNF/BNFC Class of Medicine: Eye, chapter 11

**Part A:** All medicines in Eye, chapter 11 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.:

**Part B:** The following medicines listed in Eye, chapter 11 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
All section 4 <b>except:</b> Bromfenac Diclofenac sodium Flurbiprofen Ketorolac trometamol	Acute/Specialist use only
All section 6	Specialist use only
Dexamethasone implant	Specialist use only

25

## SCHEDULE 12

### BNF/BNFC Class of Medicine: Ear, nose and oropharynx, chapter 12

**Part A:** All medicines in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

**Part B:** The following medicines listed in Ear, nose and oropharynx, chapter 12 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
Cenegermine	Specialist use only

26

## SCHEDULE 13

### BNF/BNFC Class of Medicine: Skin, chapter 13

**Part A:** All medicines in Skin, chapter 13 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.

**Part B:** The following medicines listed in Skin, chapter 13 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All injections and infusions	Acute/Specialist use only
Acitretin	Specialist use only
Alitretinoin	Specialist use only
Glycopyrronium bromide	Specialist use only
Ingenol mebutate	Acute use only
Isotretinoin	Specialist use only
Retapamulin	Acute use only

27

## SCHEDULE 14

### BNF/BNFC Class of Medicine: Vaccines, chapter 14

**Part A:** All medicines in Vaccines, chapter 14 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD to treat the following clinical conditions:

**Part B:** The following medicines listed in Vaccines, chapter 14 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All chapter 14	Acute/Specialist use only

## SCHEDULE 15

### BNF/BNFC Class of Medicine: Anaesthesia, chapter 15

**Part A:** All medicines in Anaesthesia, chapter 15 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.

**Part B:** The following medicines listed in Anaesthesia, chapter 15 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All chapter 15 <b>except</b> : Lidocaine hydrochloride cream, ointment and plaster Lidocaine with prilocaine Tetracaine	Acute/Specialist use only

## SCHEDULE 16

**BNF/BNFC Class of Medicine: Emergency treatment of poisoning, chapter 16**

**Part A:** All medicines in Emergency treatment of poisoning, chapter 16 of the current BNF/BNFC, with the exception of those listed in Part B of this schedule, may be provided in accordance with the terms given in this PGD.:

**Part B:** The following medicines listed in Emergency treatment of poisoning, chapter 16 of the current BNF/BNFC may not be provided under this PGD.

Excluded drug	Rationale
All chapter 16 except Naloxone hydrochloride	Acute/Specialist use only

## SCHEDULE 17

**BNF/BNFC Class of Medicine: Borderline Substances, appendix 2 All ACBS**

**products are excluded**